tert-Butoxy-bis-dimethylaminomethane

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-Butoxy-bis-dimethylaminomethane
• 英文别名: tert-butoxybis(dimethylamino)methane；bisdimethylamino-tert-butoxymethane；tert-butoxymethyl-dimethyl-amine；t-butoxy-bis-dimethylaminomethane；Brederick's reagent；[(Tert-butoxy)methyl]dimethylamine；N,N-dimethyl-1-[(2-methylpropan-2-yl)oxy]methanamine
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: FAIXDGTUDNPLAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dibenzyl (2S)-5-oxotetrahydro-1H-pyrrole-1,2-dicarboxylate 、 tert-Butoxy-bis-dimethylaminomethane 以100%的产率得到dibenzyl (S)-4-((dimethylamino)methylene)-5-oxopyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  Danishefsky, Samuel; Morris, Joel; Clizbe, Lane A., Heterocycles, 1981, vol. 15, # 2, p. 1205 - 1208

  摘要：

  DOI：

文献信息

• CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Aicher Thomas Daniel

  公开号：US20090111800A1

  公开（公告）日：2009-04-30

  The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

  本发明公开了具有11β-HSD类型1拮抗活性的Formula (I)的新化合物，以及制备这种化合物的方法。在另一实施例中，该发明公开了包含Formula (I)化合物的药物组合物，以及利用这些化合物和组合物治疗糖尿病、高血糖、肥胖、高血压、高脂血症、代谢综合征以及与11β-HSD类型1活性相关的其他疾病的方法。
• [EN] BICYCLO [2.2.2] ACID GPR120 MODULATORS<br/>[FR] MODULATEURS DE RÉCEPTEURS GPR120 À BASE D'ACIDE BICYCLO [2.2.2]
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014159802A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式（I）的化合物或其立体异构体，或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是GPR120 G蛋白偶联受体调节剂，可用作药物。
• Cephalosporin derivatives
  申请人：Rhone-Poulenc Sante

  公开号：US04526962A1

  公开（公告）日：1985-07-02

  New cephalosporin derivatives of the formula: ##STR1## in which R' represents a protected carboxyl radical, Hal represents a halogen atom, X.sub.1 represents a sulphur or oxygen atom or a sulphinyl radical and R represents an acyl radical or an amine-protecting radical, are useful as intermediates for the preparation of cephalosporins having antibacterial activity.

  新的头孢菌素衍生物的化学式：##STR1## 其中R'代表一个受保护的羧基，Hal代表一个卤素原子，X.sub.1代表一个硫或氧原子或一个亚砜基，R代表一个酰基或一个氨基保护基，可用作制备具有抗菌活性的头孢菌素的中间体。
• (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines
  申请人：American Cyanamid Company

  公开号：US04550166A1

  公开（公告）日：1985-10-29

  This disclosure describes novel substituted 1,2,4-triazolo[4,3-a]pyridines which possess anxioltic activity.

  这项披露描述了具有抗焦虑活性的新型取代的1,2,4-三氮唑[4,3-a]吡啶。
• [EN] PYRAZOLE DERIVATIVES AS ERK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE À TITRE D'INHIBITEURS D'ERK
  申请人：KINENTIA BIOSCIENCES LLC

  公开号：WO2012094313A1

  公开（公告）日：2012-07-12

  This invention describes substituted pyrazole derivatives of Formula I, and methods of making and using the compounds. These compounds have utility in the treatment of conditions or diseases in which modification of the activity of ERK would have a positive therapeutic outcome, for instance various cancers, psoriasis and actinic keratosis.

  这项发明描述了公式I的取代吡唑衍生物，以及制备和使用这些化合物的方法。这些化合物在治疗ERK活性修改会产生积极治疗效果的疾病或病况中具有实用性，例如各种癌症、银屑病和日光性角化症。